Rindopepimut

Drug Profile

Rindopepimut

Alternative Names: ALT 110; Brain cancer vaccine - Celldex Therapeutics; CDX-110; PF-04948568; PF-04948569; PF-4948568; PF-4948569; Rindo; Rintega; SPX 110

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Duke University; Johns Hopkins University
  • Developer Celldex Therapeutics Inc
  • Class Cancer vaccines; Peptide vaccines; Peptides
  • Mechanism of Action Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Glioblastoma
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Glioblastoma; Solid tumours

Most Recent Events

  • 08 Aug 2016 Discontinued - Phase-I for Solid tumours in USA (Intradermal)
  • 08 Aug 2016 Discontinued - Phase-II for Glioblastoma (Combination therapy, Second-line therapy or greater) in USA (Intradermal)
  • 08 Aug 2016 Discontinued - Phase-III for Glioblastoma (First-line therapy) in Australia, Canada, India, Czech Republic, Mexico, New Zealand, Taiwan, Thailand, Austria, Belgium, France, Germany, Greece, Israel, Netherlands, Spain, Switzerland, Brazil, Colombia, Hungary, Peru, United Kingdom, Italy and USA (Intradermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top